Figures computed from official regulatory filings — .
Analysttarget 42.89 USD (+87%) · consensus 4.78/5 · 9 buy · 0 hold · 0 sell
Ownershipinsiders 24.46% · institutions 71.44% · short 10.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for GH Research PLC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Schonharting Florian | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Forer Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Moore Duncantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hanley Dermot John | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Forer Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |